Literature DB >> 1901882

H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate.

L J Cooper1, J C Schimenti, D D Glass, N S Greenspan.   

Abstract

We have produced a panel of murine anti-streptococcal mAbs, expressing identical V domains and different H chain C domains, corresponding to the IgG3, IgG1, and IgG2b subclasses. We have used these mAb to evaluate the role of IgG subclass-specific C region determinants in modulating the interaction between antibody and the bacterial surface. We report, for the first time, that V region-identical murine IgG of different subclasses exhibit substantial differences in binding to specific Ag; IgG3 mAb binds more strongly to streptococci than the IgG1 and IgG2b mAb or IgG3-derived F(ab')2 fragments. Furthermore, the IgG3 mAB binds cooperatively to the bacteria, whereas the IgG1, IgG2b, and IgG3-derived F(ab')2 fragments do not exhibit significant cooperativity, which suggests that differences in Fc region structure can affect antibody binding to multivalent Ag by modulating the potential for cooperative binding. These results suggest a plausible mechanism by which murine IgG3 could be more effective, than other antibodies bearing identical V domains, but of different gamma-subclass, in mediating bacterial immunity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901882

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.

Authors:  R S Chu; T McCool; N S Greenspan; J R Schreiber; C V Harding
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Immunoglobulin KM genes in Guillain-Barré syndrome.

Authors:  Janardan P Pandey; Christian A Vedeler
Journal:  Neurogenetics       Date:  2003-02-11       Impact factor: 2.660

3.  Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses.

Authors:  N McCloskey; M W Turner; P Steffner; R Owens; D Goldblatt
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

4.  Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule.

Authors:  Thomas R Kozel; Peter Thorkildson; Suzanne Brandt; William H Welch; Julie A Lovchik; David P AuCoin; Julpohng Vilai; C Rick Lyons
Journal:  Infect Immun       Date:  2006-10-23       Impact factor: 3.441

5.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Comparison of nonhuman primate antibodies against Haemophilus influenzae type b polysaccharide with human antibodies in oligoclonality and in vivo protective potency.

Authors:  K H Kim; M K Park; C C Peeters; J T Poolman; M H Shearer; R C Kennedy; M H Nahm
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  Immunoglobulin heavy chain constant region determines the pathogenicity and the antigen-binding activity of rheumatoid factor.

Authors:  T Fulpius; F Spertini; L Reininger; S Izui
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

8.  Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.

Authors:  S L Zebedee; R K Koduri; J Mukherjee; S Mukherjee; S Lee; D F Sauer; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  Contribution of murine IgG Fc regions to antibody binding to the capsule of Burkholderia pseudomallei.

Authors:  Michael J Dillon; Rachael A Loban; Dana E Reed; Peter Thorkildson; Kathryn J Pflughoeft; Sujata G Pandit; Paul J Brett; Mary N Burtnick; David P AuCoin
Journal:  Virulence       Date:  2016-04-20       Impact factor: 5.882

10.  Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.

Authors:  Joyce M Lynch; David E Briles; Dennis W Metzger
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.